Immunotherapy Study for Patients With Stage IV Melanoma

Summary

The purpose of this study is to examine the effectiveness of immune checkpoint inhibitors (drugs called ipilimumab, nivolumab, or pembrolizumab), either given alone, or in combination with the experimental immunotherapy drug, dorgenmeltucel-L, for melanoma. We hypothesize that this form of combinatorial immunotherapy will result in tumor stabilization or shrinkage, significant prolongation of progression-free, disease-free or overall survival compared to the use of immune checkpoint inhibitors alone.

Timeline

Start

2014-06

Primary completion

2018-04-05

Completion

2021-01-05

Outcome

Outcome not reported

Stopped: “Withdrawal of IND”

Drugs

Indications